scholarly journals A phase II study of DuP 937 (Teloxantrone) in metastatic malignant melanoma: A study of the National Cancer Institute of Canada Clinical Trials Group (NCICCTG)

1993 ◽  
Vol 4 (8) ◽  
pp. 695-696
Author(s):  
T. Shore ◽  
E. Eisenhauer ◽  
I. Quirt ◽  
K. Belanger ◽  
R. Lohmann ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Malignant Melanoma ◽  
Phase Ii ◽  
National Cancer Institute ◽  
Phase Ii Study ◽  
Metastatic Malignant Melanoma

A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial

2007 ◽  
Vol 26 (3) ◽  
pp. 249-255 ◽  
Author(s):  
Christopher W. Lee ◽  
Karl Bélanger ◽  
Sanjay C. Rao ◽  
Teresa M. Petrella ◽  
Richard G. Tozer ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Malignant Melanoma ◽  
Phase Ii ◽  
National Cancer Institute ◽  
Phase Ii Study ◽  
Group Trial

Phase II study of fotemustine (F), cisplatin (CDDP), and tamoxifen (TAM) in metastatic malignant melanoma (MMM)

1993 ◽  
Vol 3 (1) ◽  
pp. 34
Author(s):  
K. A. Semb ◽  
S. Aamdal ◽  
T. Bohmann ◽  
C. Lucas ◽  
B. Gerard
Keyword(s):  
Malignant Melanoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Malignant Melanoma

scholarly journals A phase II study of bryostatin 1 in metastatic malignant melanoma

1998 ◽  
Vol 78 (10) ◽  
pp. 1337-1341 ◽  
Author(s):  
DJ Propper ◽  
V Macaulay ◽  
KJ O'Byrne ◽  
JP Braybrooke ◽  
SM Wilner ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Malignant Melanoma ◽  
Bryostatin 1

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

Cancer ◽  
2005 ◽  
Vol 103 (12) ◽  
pp. 2584-2589 ◽  
Author(s):  
Svetomir N. Markovic ◽  
Susan M. Geyer ◽  
Fitzroy Dawkins ◽  
William Sharfman ◽  
Mark Albertini ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Malignant Melanoma
Sign in / Sign up

Export Citation Format

Share Document